The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
Titolo: | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years | |
Autori: | ||
Data di pubblicazione: | 2017 | |
Rivista: | ||
Handle: | http://hdl.handle.net/11567/881777 | |
Appare nelle tipologie: | 01.01 - Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
emss-75008.pdf | Documento in versione editoriale | Open Access Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.